Dr. Thon invented PBG’s platelet platform in his laboratory at Harvard Medical School, where he served as an assistant professor. He has published more than 30 peer-reviewed papers on the production and storage of platelets. He earned his Ph.D. in biochemistry and molecular biology from the University of British Columbia, Vancouver. He retains a position as lecturer at Harvard Medical School.

Sven Karlsson is the co-founder and president of Platelet BioGenesis. He has more than a decade experience in business development and financial analysis. Prior to co-founding Platelet BioGenesis he worked as a merger and acquisition principal at J.P. Morgan, an analyst at a hedge fund, and as a venture capital investor. He earned his M.B.A. from the Stern School of Business at New York University.

Mark is a managing partner of the Qiming U.S. Healthcare Fund. Previously, he served as chief operating officer of UCB Pharma, CEO of PDL BioPharma, CEO of Signature BioScience and COO of Boehringer Mannheim Therapeutics. He serves on the boards of FivePrime Therapeutics, Dermira Inc., and Aimmune Therapeutics. He received his M.B.A. from Harvard Business School.